ArticleCurrent issues in molecular biology2025
Evaluation of Rice Traits Containing H9N2 Subtype Avian Influenza HA Protein Before Commercialization.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The H9N2 avian influenza virus (AIV) is difficult to prevent and control because of its low pathogenicity and frequent mutation. In a previous study, the HA (hemagglutinin) protein of H9N2 was expressed in a rice endosperm reactor and prepared into a subunit vaccine to immunize chickens and mice, both of which exhibited a good immunity effect. The results of the intermediate tests of the transgenic strains (AIV-1 and AIV-3) showed that the HA gene can be stably expressed. Agronomic traits, such as plant height and number of grains, were significantly optimized in the transgenic strains. Moreover, no exogenous HA genes were found in the leaves of the weeds, and it was initially determined that there was no risk of gene drift. This study provides key technical support for the commercialization of plant subunit vaccines for avian influenza viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.